COVID-19 Administration of Single-Dose Subcutaneous Anti- Spike(s) SARS-CoV-2 Monoclonal Antibodies Casirivimab and Imdevimab in High-Risk Pediatric Participants Under 12 Years of Age

NCT04992273 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

7

Enrollment

INDUSTRY

Sponsor class

Stopped Emerging SARS-CoV-2 variants impacting susceptibility to study drug

Conditions

COVID-19

Interventions

DRUG: casirivimab+imdevimab

Sponsor

Regeneron Pharmaceuticals